Peer-reviewed veterinary case report
How ronidazole medicine moves through healthy cats after IV and oral
By LeVine, Dana N et al.·Published in Journal of feline medicine and surgery·2011·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Ronidazole pharmacokinetics after intravenous and oral immediate-release capsule administration in healthy cats.
- Species:
- cat
Plain-English summary
A group of six healthy cats received either an intravenous (IV) dose or an oral capsule of ronidazole, a medication used to treat a specific intestinal infection called Tritrichomonas foetus. The study found that the oral form of the medication was quickly absorbed into the bloodstream, with nearly all of it being utilized by the cats. However, the way the drug is processed in their bodies could lead to potential side effects, such as neurotoxicity, if given too frequently. The researchers suggest that giving the medication less often might be safer while still being effective for treating the infection.
People also search for: cat Tritrichomonas foetus treatment · ronidazole side effects in cats · how often to give ronidazole to cats
Abstract
Ronidazole (RDZ) is an effective treatment for feline Tritrichomonas foetus infection, but has produced neurotoxicity in some cats. An understanding of the disposition of RDZ in cats is needed in order to make precise dosing recommendations. Single-dose pharmacokinetics of intravenous (IV) RDZ and immediate-release RDZ capsules were evaluated. A single dose of IV RDZ (mean 9.2mg/kg) and a 95mg immediate-release RDZ capsule (mean 28.2mg/kg) were administered to six healthy cats in a randomized crossover design. Plasma samples were collected for 48 h and assayed for RDZ using high pressure liquid chromatography (HPLC). Systemic absorption of oral RDZ was rapid and complete, with detection in the plasma of all cats by 10 min after dosing and a bioavailability of 99.64 (±16.54)%. The clearance of RDZ following IV administration was 0.82 (±0.07) ml/kg/min. The terminal half-life was 9.80 (±0.35) and 10.50 (±0.82) h after IV and oral administration, respectively, with drug detectable in all cats 48h after both administrations. The high oral bioavailability of RDZ and slow elimination may predispose cats to neurotoxicity with twice-daily administration. Less frequent administration should be considered for further study of effective treatment of T foetus-infected cats.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21239199/